InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
| Product | Citation | Year | Journal | Authors | Page |
|---|---|---|---|---|---|
| TL8-506 | IRF1 governs the differential interferon-stimulated gene responses in human m... | 2021 | Cell Rep. | Song R. et al. | DOI: 10.1016/j.celrep.2021.108891 |
| LPS-EB (LPS from E. coli O111:B4) | IRF1 governs the differential interferon-stimulated gene responses in human m... | 2021 | Cell Rep. | Song R. et al. | DOI: 10.1016/j.celrep.2021.108891 |
| Mouse TLR4 Reporter HEK293 Cells (NF-κB) | Direct impact of commonly used dietary emulsifiers on human gut microbiota. | 2021 | Microbiome. | Naimi S. et al. | DOI: 10.1186/s40168-020-00996-6 |
| Mouse TLR5 Reporter HEK293 Cells (NF-κB) | Direct impact of commonly used dietary emulsifiers on human gut microbiota. | 2021 | Microbiome. | Naimi S. et al. | DOI: 10.1186/s40168-020-00996-6 |
| QUANTI-Blue™ | Direct impact of commonly used dietary emulsifiers on human gut microbiota. | 2021 | Microbiome. | Naimi S. et al. | DOI: 10.1186/s40168-020-00996-6 |
| Puromycin | SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. | 2021 | Cell | Hoffmann M. et al. | DOI: 10.1016/j.cell.2021.03.036 |
| Anti-hTLR1 Neutralizing mAb | A putative exosporium lipoprotein GBAA0190 of Bacillus anthracis as a potenti... | 2021 | BMC Immunol. | Jeon J.H. et al. | DOI: 10.1186/s12865-021-00414-y |
| Anti-hTLR6 Neutralizing mAb | A putative exosporium lipoprotein GBAA0190 of Bacillus anthracis as a potenti... | 2021 | BMC Immunol. | Jeon J.H. et al. | DOI: 10.1186/s12865-021-00414-y |
| SB203580 | ProBDNF induces sustained elevation of intracellular Ca 2+ possibly mediated ... | 2021 | Glia | Mizoguchi Y. et al. | DOI: 10.1002/glia.23996 |
| LPS-EB (LPS from E. coli O111:B4) | The effects of myelin on macrophage activation are phenotypic specific via cP... | 2021 | Sci Rep. | Kopper T.J. et al. | DOI: 10.1038/s41598-021-85863-6 |
| LPS-B5 (LPS from E. coli O55:B5) | Macrophage-HIF1α signaling in carotid artery stenosis. | 2021 | Am J Pathol. | Kim G.D. et al. | DOI: 10.1016/j.ajpath.2021.03.008 |
| Imiquimod VacciGrade™ (R837) | Imiquimod accelerated antitumor response by targeting lysosome adaptation in ... | 2021 | J Invest Dermatol. | Chang S.H. et al. | DOI: 10.1016/j.jid.2021.01.034 |
| LPS-EB (LPS from E. coli O111:B4) | Production of IL-1β, IL-6 and CXCL8 by endometrium of crossbred heifers stimu... | 2021 | Anim Reprod Sci. | Pimenta Nunes P. et al. | DOI: 10.1016/j.anireprosci.2021.106736 |
| Plasmocin® - Mycoplasma Elimination Reagent | Local administration of porcine immunomodulatory, chemotactic and angiogenic ... | 2021 | Bioact Mater. | Monguió-Tortajada M. et al. | DOI: 10.1016/j.bioactmat.2021.02.026 |
| Puromycin | FOXP1 drives osteosarcoma development by repressing P21 and RB transcription ... | 2021 | Oncogene | Li H. et al. | DOI: 10.1038/s41388-021-01742-4 |
| 2'3'-c-di-AM(PS)2 (Rp,Rp) VacciGrade™ | Combination of Interleukin-15 With a STING Agonist, ADU-S100 Analog: A Potent... | 2021 | Front Oncol. | Esteves A.M. | DOI: 10.3389/fonc.2021.621550 |
| ADU-S100 | Combination of Interleukin-15 With a STING Agonist, ADU-S100 Analog: A Potent... | 2021 | Front Oncol. | Esteves A.M. | DOI: 10.3389/fonc.2021.621550 |
| 2'3'-cGAMP Control | Combination of Interleukin-15 With a STING Agonist, ADU-S100 Analog: A Potent... | 2021 | Front Oncol. | Esteves A.M. | DOI: 10.3389/fonc.2021.621550 |
| PMA - Phorbol myristate acetate | Ex vivo characterization of Breg cells in patients with chronic Chagas disease. | 2021 | Sci Rep. | Girard M.C. et al. | DOI: 10.1038/s41598-021-84765-x |
| C14-Tri-LAN-Gly | NOD1 Agonist Protects Against Lipopolysaccharide and D-Galactosamine-Induced ... | 2021 | Front Immunol. | Jia F. et al. | DOI: 10.3389/fimmu.2021.603192 |